Article
NASP Launches Website to Combat Harmful DIR Fees Tops SPT Week in Review
Author(s):
Top news of the week from Specialty Pharmacy Times.
5. Treatment-Resistant Breast Cancer May Have Met Its Match with First-In-Class Drugs
The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer. Read more…
4. Influenza Triggers Relapse in Multiple Sclerosis
Upper respiratory infections cause immune cells to travel to the brain, prompting multiple sclerosis to relapse. Read more…
3. FDA Approves Acute Lymphoblastic Leukemia Drug
Inotuzumab ozogamicin (Besponsa) granted FDA approval to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read more…
2. Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis
Research finds that a robust pipeline of PsA agents will put pressure on Cosentyx. Read more…
1. NASP Launches Website to Combat Harmful DIR Fees
StopDIRfees.com provides education about direct and indirect remuneration fees. Read more…
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
